[go: up one dir, main page]

NO20072934L - Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt - Google Patents

Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt

Info

Publication number
NO20072934L
NO20072934L NO20072934A NO20072934A NO20072934L NO 20072934 L NO20072934 L NO 20072934L NO 20072934 A NO20072934 A NO 20072934A NO 20072934 A NO20072934 A NO 20072934A NO 20072934 L NO20072934 L NO 20072934L
Authority
NO
Norway
Prior art keywords
remodeling
treatment
heart failure
left ventricular
ranolazon
Prior art date
Application number
NO20072934A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20072934L publication Critical patent/NO20072934L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse vedrører en fremgangsmåte for å reversere venstre ventrikkelremodellering ved kombinert administrering av terapeutisk effektive mengder av ranolazin og minst ett samtidig remodellerende middel, som kan være en ACEinhibitor, en ARB eller en betablokker. Fremgangsmåten finner anvendelse i behandlingen av hjertesvikt. Denne oppfinnelsen vedrører også farmasøytiske forrnuleringer som er passende for slike kombinerte administreringer.
NO20072934A 2004-11-09 2007-06-08 Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt NO20072934L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09
PCT/US2005/040824 WO2006053161A1 (en) 2004-11-09 2005-11-09 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Publications (1)

Publication Number Publication Date
NO20072934L true NO20072934L (no) 2007-08-08

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072934A NO20072934L (no) 2004-11-09 2007-06-08 Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt

Country Status (15)

Country Link
US (2) US20060111361A1 (no)
EP (1) EP1809289A1 (no)
JP (1) JP2008519770A (no)
KR (1) KR20070084063A (no)
CN (1) CN101072562A (no)
AU (1) AU2005304421A1 (no)
BR (1) BRPI0517650A (no)
CA (1) CA2586840A1 (no)
IL (1) IL183056A0 (no)
MX (1) MX2007005367A (no)
NO (1) NO20072934L (no)
RU (1) RU2007121707A (no)
SG (1) SG156681A1 (no)
WO (1) WO2006053161A1 (no)
ZA (1) ZA200703697B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
JP5522663B2 (ja) * 2006-09-08 2014-06-18 カーディオポリマーズ， インコーポレイテッド 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
WO2008080012A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
JP2010523264A (ja) * 2007-04-11 2010-07-15 ヘンリー フォード ヘルス システム 心臓の静脈系を用いた心臓の修復、リサイジング、およびリシェイピング
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2009202685B1 (en) 2009-06-30 2010-08-19 Ino Therapeutics Llc Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
JP6998942B2 (ja) * 2016-09-19 2022-01-18 アビオメド インコーポレイテッド 心機能を定量化し、心臓の回復を促進する心血管補助システム

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719558T3 (da) * 1989-06-23 2002-10-07 Syntex Llc Ranolzin og beslægtede piperazin til anvendelse ved behandling af chocktilstande
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
MXPA02007639A (es) * 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
IL183056A0 (en) 2007-10-31
RU2007121707A (ru) 2008-12-20
EP1809289A1 (en) 2007-07-25
WO2006053161A8 (en) 2006-09-14
MX2007005367A (es) 2007-06-18
AU2005304421A1 (en) 2006-05-18
ZA200703697B (en) 2008-09-25
US20060111361A1 (en) 2006-05-25
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
CN101072562A (zh) 2007-11-14
WO2006053161A1 (en) 2006-05-18
KR20070084063A (ko) 2007-08-24
CA2586840A1 (en) 2006-05-18
JP2008519770A (ja) 2008-06-12
BRPI0517650A (pt) 2008-10-14

Similar Documents

Publication Publication Date Title
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
NO20075400L (no) Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
NO20090469L (no) Substituerte piperidiner som oker P53-aktiviteten, og anvendelse derav
AR074313A1 (es) Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20080187L (no) Aspartylproteaseinhibitorer
NO20092569L (no) Inhibitorer av Akt-aktivitet
AR119158A1 (es) Tratamientos de angioedema hereditario
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20071446L (no) Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
BRPI0510110A (pt) método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
NO20083333L (no) Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
MX2021003845A (es) Composiciones para reducir el acido urico serico.
ECSP11011029A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con una eficacia mejorada sobre la terapia con warfarina convencional.
WO2020047352A8 (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
AR120799A1 (es) 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application